Etisulergine

Etisulergine
Clinical data
Other namesCQ-32084; CQ 32-084; N,N-Diethyl-N'-(6-methylergolin-8α-yl)sulfamide
Drug classDopamine agonist; Prolactin inhibitor; Antiparkinsonian agent
Identifiers
  • (6aR,9S,10aR)-9-(diethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H28N4O2S
Molar mass376.52 g·mol−1
3D model (JSmol)
  • CCN(CC)S(=O)(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
  • InChI=1S/C19H28N4O2S/c1-4-23(5-2)26(24,25)21-14-10-16-15-7-6-8-17-19(15)13(11-20-17)9-18(16)22(3)12-14/h6-8,11,14,16,18,20-21H,4-5,9-10,12H2,1-3H3/t14-,16+,18+/m0/s1
  • Key:YHEIHLVIKSTGJE-YXJHDRRASA-N

Etisulergine (INNTooltip International Nonproprietary Name; developmental code name CQ-32084 or CQ 32-084) is a drug of the ergoline family described as a dopamine agonist, prolactin inhibitor, and antiparkinsonian agent which was never marketed.[1][2][3][4][5][6] It is closely related in chemical structure to lisuride and is also similar in structure to lysergic acid diethylamide (LSD).[1][2] Etisulergine was first described in the literature by at least 1977.[1][5]

See also

References

  1. ^ a b c Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. p. 524. ISBN 978-1-4757-2085-3. Retrieved 30 June 2025.
  2. ^ a b Negwer M, Scharnow H (2001). Organic-chemical Drugs and Their Synonyms: An International Survey. Wiley-VCH. p. 1829. ISBN 978-3-527-30247-5. Retrieved 30 June 2025.
  3. ^ Milne GW (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Routledge. ISBN 978-1-351-78989-9. Retrieved 30 June 2025.
  4. ^ Casagrande C, Bertolini G (1996). "Perspectives in the design and application of dopamine receptor agonists". Pharmacochemistry Library. Vol. 24. Elsevier. pp. 67–84. doi:10.1016/s0165-7208(96)80008-0. ISBN 978-0-444-82204-8. Retrieved 30 June 2025.
  5. ^ a b Flückiger E, Briner U, Bürki HR, Marbach P, Wagner HR, Doepfner W (December 1979). "Two novel prolactin release-inhibiting 8 alpha-amino-ergolines". Experientia. 35 (12): 1677–1678. doi:10.1007/BF01953267. PMID 520501.
  6. ^ Pakkenberg H, Jensen I (1983). "Treatment of Parkinson's disease with the ergoline derivatives CQ 32-084 and CU 32-085". Advances in Neurology. 37: 151–157. PMID 6344587.



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.